dc.date.accessioned | 2020-12-18T19:34:30Z | |
dc.date.available | 2020-12-18T19:34:30Z | |
dc.date.issued | 2020-12-18 | |
dc.identifier.uri | https://iris.paho.org/handle/10665.2/52719 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1159 | |
dc.description.abstract | Summary of rapid systematic reviews, from the 8th edition of the document and above. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infecitous Diseases | en_US |
dc.subject | Systematic Reviews | en_US |
dc.subject | Therapeutics | en_US |
dc.subject | Meplazumab | en_US |
dc.subject | Ivermectin | en_US |
dc.subject | Siltuximab | en_US |
dc.subject | Danoprevir | en_US |
dc.subject | Tocilizumab | en_US |
dc.subject | Favipiravir | en_US |
dc.subject | Darunavir | en_US |
dc.subject | Nelfinavir | en_US |
dc.subject | Remdesivir | en_US |
dc.subject | Cloroquine | en_US |
dc.subject | Hydroxychloroquine | en_US |
dc.subject | Convalescent Plasma | en_US |
dc.subject | Corticosteroids | en_US |
dc.subject | Umifenovir | en_US |
dc.subject | Lopinavir | en_US |
dc.subject | Ritonavir | en_US |
dc.title | Ongoing Living Update of Potential COVID-19 Therapeutics Options: Summary of Evidence. Rapid Review | en_US |
eihealth.country | Regional, Americas (PAHO/OPS) | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | WHO / PAHO Guidance | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.contributor.corporatename | Pan American Health Organization | en_US |